News
-
-
-
PRESS RELEASE
EQS-Adhoc: EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor
EMA grants PRIME status to Pentixapharm’s lead candidate Ga68-PentixaFor, offering early and proactive support for radiodiagnostic development in primary aldosteronism. PentixaFor aims to transform diagnostic subtyping with non-invasive PET imaging targeting CXCR4 -
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed
Pentixapharm Holding AG sets IPO placement price at EUR 5.10 per share, placing all 3.9 million offer shares. Gross proceeds reach EUR 19.9 million. Post-money market capitalization at EUR 126.5 million -
PRESS RELEASE
Original-Research: Pentixapharm Holding AG (von BankM AG): n.a.
Pentixapharm Holding AG von BankM AG eingestuft. Präziser Theranostic-Ansatz mit validiertem Target. Potenzial in Präzisionsonkologie. Risikoadjustierte Bewertung des Eigenkapitals. Vollständige Analyse unter: http://www.more-ir.de/d/30855.pdf